Overview

Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma

Status:
Not yet recruiting
Trial end date:
2026-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety and efficacy of magrolimab in combination with pembrolizumab in patients with Hodgkin lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
Stanford University
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Antibodies
Antibodies, Monoclonal
Antineoplastic Agents, Immunological
Hu5F9-G4
Immunoglobulins
Magrolimab
Pembrolizumab